Skip to content
Screener

Aardvark Therapeutics, Inc. AARD Q4 2025 Annual earnings

Reported March 23, 2026

Revenue-
EPS-$0.81Beat by $0.02
EPS estimate-$0.83

Next report

Nov 12, 2026 (in a month)
EPS estimate-$0.74

Financials

Q4 2025

Income statement

See full
Revenue-—
Operating income-$18.7M-97.9%
Net income-$17.6M-100%
EPS (diluted)-$0.81+62.8%

Balance sheet

See full
Cash & equivalents$47.1M-23.7%
Total debt$441.0K-43.4%
Total equity$106.6M+295%
Total assets$117.2M+51.2%

Cash flow

See full
Operating cash flow-$16.8M-118%
CapEx--100%
Free cash flow-$16.8M-117%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$285.77M—
Enterprise value$239.16M—

Returns & leverage

See full
Debt / equity0×—
Current ratio10.6×-4.4×

FAQ

When did Aardvark Therapeutics, Inc. report Q4 2025 earnings?
Aardvark Therapeutics, Inc. (AARD) reported Q4 2025 earnings on March 23, 2026.
What were Aardvark Therapeutics, Inc.'s Q4 2025 revenue and EPS?
Aardvark Therapeutics, Inc. reported revenue of - and eps of $-0.81 for Q4 2025.
Did Aardvark Therapeutics, Inc. beat estimates in Q4 2025?
EPS beat the consensus estimate of $-0.83 by $0.02.
How did Aardvark Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 19.1% from $-0.68.
Where can I find Aardvark Therapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-119727) and the 10-K periodic report (0001193125-26-119770) directly on SEC EDGAR. The filing index links above go to sec.gov.